FDA approves Uceris rectal foam

FDA approved an NDA for Uceris budesonide rectal foam from Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) to induce remission of mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal verge.

Salix intends to launch the foam formulation of the glucocorticosteroid in 1Q15. The company currently markets a once-daily tablet formulation of Uceris in the U.S. for the induction of remission in patients with active, mild to moderate UC. ...